Pfizer’s tilrekimig hits Phase 2 goal, moves to Phase 3 trials
Pfizer's tilrekimig Phase 2 atopic dermatitis trial hit its primary endpoint, with the drug now advancing into Phase 3 studies in two indications.
Markets
Delayed ยท 00:11 UK
Topic
Every Financial News story tagged dermatology, newest first.
Pfizer's tilrekimig Phase 2 atopic dermatitis trial hit its primary endpoint, with the drug now advancing into Phase 3 studies in two indications.